Loading...
•
Jul 31, 2024
Cooper Q3 2024 Earnings Report
CooperCompanies reported strong Q3 2024 results, driven by revenue growth in both CooperVision and CooperSurgical segments.
Key Takeaways
CooperCompanies announced an 8% increase in revenue to $1,002.8 million for Q3 2024. GAAP EPS increased by 22% to $0.52, and non-GAAP EPS increased by 14% to $0.96. The company raised its fiscal year 2024 financial guidance.
Revenue increased 8% year-over-year to $1,002.8 million.
CooperVision (CVI) revenue was up 7% to $675.6 million.
CooperSurgical (CSI) revenue was up 9% to $327.2 million.
GAAP diluted earnings per share (EPS) of $0.52, up $0.09 or 22% from last year's third quarter.
Cooper
Cooper
Cooper Revenue by Segment
Cooper Revenue by Geographic Location
Revenue by Segment
Toric & Multifocal Revenue
CapyFin.comSphere & Other Revenue
CapyFin.comOffice & Surgical Revenue
CapyFin.comFertility Revenue
CapyFin.comRevenue by Geographic Location
Americas Revenue
CapyFin.comEMEA Revenue
CapyFin.comAsia Pacific Revenue
CapyFin.com Forward Guidance
The Company raised its fiscal year 2024 financial guidance.
Positive Outlook
- Fiscal 2024 total revenue of $3,892 - $3,913 million (organic growth of 8% to 8.5%)
- CVI revenue of $2,606 - $2,618 million (organic growth of 9% to 9.5%)
- CSI revenue of $1,286 - $1,294 million (organic growth of 5.5% to 6.5%)
- Fiscal 2024 non-GAAP diluted EPS of $3.64- $3.67
- Fiscal fourth quarter 2024 total revenue of $1,015 - $1,036 million (organic growth of 7% to 9.5%)
Revenue & Expenses
Visualization of income flow from segment revenue to net income